Mirador Analytics extended Board of Directors.
Mirador Analytics has bolstered its Board of Directors with the addition of two life sciences executives from Thomson Reuters Scientific & Healthcare and Kyowa Kirin International.
Mirador Analytics, the leading HIPAA Expert Determination provider, recently announced the extension of its Board of Directors, adding two prominent life sciences former executives, Shahir Kassam-Adams, Corporate Development at Datavant, former Executive Vice President of Thomson Reuters Scientific & Healthcare, and Dr. Tom Stratford, CEO of Kelso Pharma, former CEO and President of Kyowa Kirin International. The extended Board, which consists of five members, also includes Jamie Blackport, Founder, CEO, and President; Jamie Gray, Chief Operating Officer; and Chris Watson, Head of IT & Security, all of Mirador Analytics.
The two new board members bring broad and deep expertise to the company, which will help guide its future strategy and growth.
Kassam-Adams was co-founder of Universal Patient Key (UPK) – now a part of Datavant. In addition, he has been an operator or early investor in multiple health care technology-enabled start-ups and companies, including Aileron Solutions, Social Safeguard, TGaS, Decision Resources Group (DRG), and Thomson Reuters Scientific & Healthcare. Shahir has an MS in Computer Science from Johns Hopkins University and an MBA from the Wharton School of the University of Pennsylvania.
Stratford is a highly experience life sciences executive with a 25+ year track record in establishing and building businesses across Europe, the Middle East, and the USA. He was one of the first early employees in ProStrakan as it grew to be a public company. Following the acquisition by Kyowa Kirin, Tom spent nine years leading the European and US teams as CEO/President with a combined turnover approaching $1bn. Tom currently serves as a NED for Axol Biosciences and CEO of Kelso Pharma.
Blackport has a 20+ year commercial and medical affairs global pharmaceutical career where he specialized in successfully helping small and mid-sized biopharma companies commercially develop, transact, and launch products worldwide. Jamie led the International Marketing and Medical Affairs of Kyowa Kirin International and AstraZeneca. He started Mirador Analytics with his fellow founders as they recognized health care organizations needed support to realize the full potential of their data and analyses. Offering that support would, in turn, help support innovation and growth in the industry and advance global health care.
About Mirador Analytics
Mirador Analytics supports organizations across the health care ecosystem to ensure the privacy of individuals is protected through expert evaluation of data de-identification and the use of proprietary software solutions. Mirador Analytics aims to achieve high levels of privacy for individuals while maximizing data utility to allow for innovation, efficiency, and development in health care. For more information, visit www.miradoranalyitcs.com
Jamie Blackport, email@example.com
Eszter Vuity, firstname.lastname@example.org
Syntegra Partners with Mirador Analytics to Certify Industry-Wide Privacy Metrics for Synthetic Data
SAN FRANCISCO, CA and WILMINGTON, DE, [Date TBD] – Today, Syntegra, a leader in synthetic healthcare data generation, and Mirador Analytics, the leading HIPAA expert determination provider, announced a partnership to certify Syntegra’s metrics for validating the privacy of synthetic data. This partnership is another step forward in both companies’ broader goal of enabling easier, faster and safer access to healthcare data to advance research efforts.
Syntegra is working with Mirador to review and certify Syntegra’s privacy techniques used to validate that their synthetic data fully protects patient privacy, ensuring no patient can be re-identified via the synthetic data. Once the project is complete later this year, the companies plan to publish materials that will support application and understanding of these privacy-preserving techniques for a wider audience to aid industry thought-leadership/guidelines.
Syntegra is leading the creation of privacy metrics for synthetic data, enabling synthetic healthcare data to be clearly assessed by any organization within a risk and privacy governance structure they already understand. Through this work, Syntegra and Mirador are paving the way for standard, industry-wide metrics to ensure patient privacy while enabling greater usage and value of healthcare data.
Maintaining patient privacy is paramount, but the industry must discover better ways of securely sharing and accessing patient data to advance the field of medicine, and synthetic data is an important mechanism to address this need. Rather than assuming synthetic data is inherently private simply because it’s synthetic, Syntegra is taking it a further step by partnering with Mirador to certify their metrics. This is particularly important when synthetic data is generated from actual health records.
“Any medical innovation requires evidence, and evidence requires data. To improve outcomes, it is imperative that we find new ways of leveraging healthcare data while protecting patient privacy,” said Michael D. Lesh, MD, founder and CEO of Syntegra. “We’re thrilled to partner with Mirador to help prove that Syntegra-generated synthetic data successfully prevents disclosure of patient information.”
"With the current industry focus on big data in healthcare, the amount of data created in the next three years is expected to be more than the data created over the past three decades. There’s always a residual risk to privacy in data, and with exponential growth expected, we must explore all techniques we have available to us to minimize risk while absorbing the utility. - Said Jamie Blackport, CEO and Founder of Mirador Analytics. "We're thrilled to work with Syntegra to help them define better industry-standards of synthetic data metrics we hope to be a game-changer in data privacy protection in the future."